Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM159PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7919.042 | 1.0285 | 1.0152 | 3.7203 | |
| SUM159PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7919.042 | 0.9933 | 0.9964 | 3.7203 | |
| SUM159PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7919.042 | 1.0093 | 1.0050 | 3.7203 | |
| SUM159PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7919.042 | 0.9807 | 0.9895 | 3.7203 | |
| SUM159PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7919.042 | 0.9929 | 0.9962 | 3.7203 | |
| SUM159PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.137 | uM | 7919.042 | 0.9682 | 0.9827 | 3.7203 | |
| SUM159PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.685 | uM | 7919.042 | 0.9162 | 0.9535 | 3.7203 | |
| SUM159PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7920.018 | 1.0088 | 1.0040 | 4.3723 | |
| SUM159PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7920.018 | 1.0306 | 1.0138 | 4.3723 | |
| SUM159PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7920.018 | 0.9340 | 0.9690 | 4.3723 | |
| SUM159PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7920.018 | 1.0359 | 1.0162 | 4.3723 | |
| SUM159PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7920.018 | 0.9606 | 0.9817 | 4.3723 | |
| SUM159PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7920.018 | 0.9557 | 0.9794 | 4.3723 | |
| SUM159PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7920.018 | 0.9915 | 0.9961 | 4.3723 | |
| SUM159PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.137 | uM | 7920.018 | 0.9579 | 0.9804 | 4.3723 | |
| SUM159PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.685 | uM | 7920.018 | 0.8935 | 0.9492 | 4.3723 | |
| SUM159PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 9042.018 | 0.7309 | 0.8160 | 3.2484 | |
| SUM159PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 9042.018 | 0.9797 | 0.9874 | 3.2484 | |
| SUM159PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 9042.018 | 0.6378 | 0.7414 | 3.2484 | |
| SUM159PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.000219 | uM | 9042.018 | 0.8598 | 0.9092 | 3.2484 | |
| SUM159PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0011 | uM | 9042.018 | 0.8541 | 0.9052 | 3.2484 | |
| SUM159PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00548 | uM | 9042.018 | 0.9867 | 0.9918 | 3.2484 | |
| SUM159PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0274 | uM | 9042.018 | 0.6981 | 0.7905 | 3.2484 | |
| SUM159PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.137 | uM | 9042.018 | 0.6805 | 0.7765 | 3.2484 | |
| SUM159PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.685 | uM | 9042.018 | 0.6765 | 0.7732 | 3.2484 |